SSKN Strata Skin Sciences Inc

STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended September 30, 2024 and provides a corporate update.

Third Quarter 2024 Highlights

• Revenue in the third quarter of 2024 was $8.8 million (-1% YOY) vs. $8.9 million in the third quarter of 2023
  • Global net recurring revenue in the third quarter of 2024 was $5.4 million (+2% YOY) vs. $5.3 million in the third quarter of 2023
  • Gross domestic XTRAC® recurring billings were $4.8 million (-2% YOY) in the third quarter of 2024 vs. $4.9 million in the third quarter of 2023
  • Revenue per domestic XTRAC® system increased to $5,332 (+2% YOY) on 873 systems during the third quarter vs. $5,233 per system on 929 systems in the prior year period

• Adjusting for a one-time expense of $1.8 million, total non-GAAP operating expenses in the third quarter of 2024 were $5.2 million (-7% YOY) vs. $5.6 million in the third quarter of 2023. The one-time item is an accrual following the resolution of a New York state tax audit covering the period from 2014 to 2017, which the Company recorded as a General and Administrative expense
• Non-GAAP operating profit, excluding the one-time accrual item described above, was $128,000 in the quarter, representing the first time the Company has generated an operating profit since the Company’s major refinancing in early 2018
• Domestic installed base of 873 XTRAC® devices under the Company’s recurring revenue business model at September 30, 2024 vs. 882 XTRAC® devices at June 30, 2024 and 923 XTRAC® devices at December 31, 2023, as the Company continues to realign its assets and remove underperforming accounts
• Domestic installed base of 135 TheraClear®X devices at September 30, 2024 vs. 117 TheraClear®X devices at June 30, 2024 and 92 TheraClear®X devices at December 31, 2023

Recent Corporate Highlights

• Filed a complaint against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group, citing unfair competition under federal and state laws regarding the marketing and sales of competitive laser devices. Following a joint stipulation by the parties, on November 8, 2024 a court order was entered in the United States District Court for the Eastern District of Pennsylvania enjoining LaserOptek, The Pinnacle Group, and all those acting at their direction from engaging in any sales, advertising, marketing or promotion of LaserOptek’s Pallas lasers that states or implies, directly or indirectly, that treatments with Pallas laser systems are reimbursable using CPT Codes 96920-96922. The court order also barred LaserOptek and The Pinnacle Group from engaging in any sales, advertising, marketing or promotion of LaserOptek’s Pallas lasers in the United States that includes any false or misleading statements regarding the Pallas lasers or STRATA’s lasers.
• Closed a registered direct offering on July 23, 2024 that raised $2.1 million in gross proceeds through the sale of 665,136 shares of common stock at an average purchase price of $3.16/share, with participation from insiders and existing institutional shareholders
• Received approval for the XTRAC Momentum® 1.0 device in Japan and began immediate commercial rollout through the Company’s Japanese strategic partner and distributor JMEC Co., Ltd. Six Momentum units have already been placed in Japan under the Company’s recurring revenue business model that are included in the 19 XTRAC devices placed during 2024
• Announced a publication in the July 11, 2024 issue of the Journal of Cosmetic and Laser Therapy of a multi-treatment study finding the TheraClear®X Acne Therapy System reduced lesions and associated skin redness with improvement in skin texture and pore size after one to three treatments while being well tolerated, offering benefits as monotherapy and/or as an adjuvant
• STRATA’s XTRAC® excimer laser was the focus of two lectures at the 75th Annual Meeting of the Chubu Branch of the Japanese Dermatological Association held in Nagoya, Japan
• The XTRAC® excimer laser was featured at the 2024 Fall Clinical Dermatology Conference held in Las Vegas in a poster presentation titled, Targeted 308-nm Excimer Laser: A Safe and Effective Solution for Inflammatory Skin Disorders. Additionally, numerous KOL speakers emphasized the significance of excimer lasers as a proven treatment option for psoriasis, vitiligo, and eczema

“The 2% year-over-year increase in revenue per XTRAC® system in the third quarter of 2024 illustrates progress in the Company’s turnaround. This increase compares favorably to roughly flat revenue growth per system last quarter and a decline of 10% in fiscal 2023 over fiscal 2022. This metric, along with essentially flat year-over-year revenue and global net recurring revenue in the third quarter, points to additional evidence that our business has stabilized,” commented STRATA’s President and CEO Dr. Dolev Rafaeli. “More importantly, gross margin as a percent of revenue continued to strengthen for the third consecutive quarter, reaching 60.3% in the third quarter, an improvement from 56.0% in the prior year period and up from 58.5% in the second quarter of 2024. Additionally, total operating expenses declined to $5.2 million in the third quarter from $5.6 million in the third quarter of 2023 and from $5.4 million in the second quarter of 2024. Altogether, these trends allowed us to generate a non-GAAP operating profit in the third quarter of 2024, the first time since 2018 that this has occurred.

“Our DTC efforts remain a key focus of our turnaround strategy, and we continue to see signs of execution on this front. During the third quarter we expanded the targeted geographies and initiated Spanish language advertisement. Thus far in 2024, we have scheduled over 1,900 DTC-driven new patient appointments, as compared to 8 in 2023, and exceeded the 1,643 scheduled in fiscal 2019 before the Covid-19 pandemic sharply curtailed office visits across the healthcare system.

“We continue to examine our installed base of XTRAC® devices in an effort to maximize their utilization. Our domestic base of installed XTRAC® devices declined from 882 at the end of the second quarter to 873 at the end of the third quarter. The combination of our renewed DTC marketing efforts and our efforts to maximize utilization of our XTRAC® devices with our dermatology partners helped us achieve the highest quarterly average revenue per device from our XTRAC® installed base since the end of 2022.

“TheraClear®X device placements continue to grow and reached 135 in the third quarter, up from 117 at the end of the second quarter. The adoption of the non-cash, insurance-reimbursed billing has accelerated in 2024 after being non-existent in 2023, as we have helped secure insurance pre-authorization for our partnered clinics in over 2,000 patients. Additionally, published studies, such as the one in the July 11, 2024 issue of the Journal of Cosmetic and Laser Therapy, continue to point to improved patient outcomes for the treatment of acne. At the recent 2024 Fall Clinical Dermatology Conference, a poster presentation titled, Targeted 308-nm Excimer Laser: A Safe and Effective Solution for Inflammatory Skin Disorders was presented that also highlighted the benefits of the TheraClear®X device

“We strengthened our balance sheet in July 2024 with a $2.1 million equity raise that had notable participation from existing shareholders and management. This financing, along with continued improving operating and financial performance, should help lead us to profitability and sustainable cash flow generation, which was the goal of our multifaceted strategy put in motion at the beginning of 2024,” concluded Dr. Rafaeli.

Third Quarter 2024 Financial Results

Revenue for the third quarter of 2024 was $8.8 million, as compared to revenue of $8.9 million for the third quarter of 2023. Global recurring revenue for the third quarter of 2024 was $5.4 million, as compared to global recurring revenue of $5.3 million for the third quarter of 2023. Equipment revenue was $3.4 million for the third quarter of 2024, as compared to $3.6 million for the third quarter of 2023.

Gross profit for the third quarter of 2024 was $5.3 million, or 60.3% of revenue, as compared to $5.0 million, or 56.0% of revenue, for the third quarter of 2023.

Selling and marketing costs for the third quarter of 2024 were $3.0 million, as compared to $3.0 million for the third quarter of 2023. General and administrative costs, including the $1.8 million accrual for New York state taxes previously referenced, for the third quarter of 2024 were $3.7 million, as compared to $2.3 million for the third quarter of 2023.

Net loss for the third quarter of 2024 was $2.1 million, or a net loss of $0.53 per basic and diluted common share, as compared to a net loss of $1.1 million, or a net loss of $0.30 per basic and diluted common share, in the third quarter of 2023.

Cash, cash equivalents, and restricted cash at September 30, 2024 were $8.4 million.

Third Quarter 2024 Earnings Conference Call

STRATA management will host a conference call at 4:30 p.m. ET on Wednesday, November 13, 2024 to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.

To listen to the conference call, interested parties within the U.S. should dial 1-844-481-2523 (domestic) or 1-412-317-0552 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the STRATA Skin Sciences, Inc. conference call.

The conference call will also be available through a live webcast that can be accessed at STRATA Skin Sciences 3Q24 Earnings Webcast.

A telephonic replay of the call will be available until November 20, 2024 by dialing 1-877-344-7529 (or 1-412-317-0088 for international callers) and using replay access code 4851779. To access the replay using an international dial-in number, please see here.

A webcast earnings call replay will be available approximately one hour after the live call and remain accessible until May 13, 2025.

Non-GAAP Financial Measures

STRATA has determined to supplement its consolidated financial statements, prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), presented elsewhere within this report, with certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP gross profit, which excludes the non-cash expense of amortization of acquired intangible assets classified as cost of revenues, and non-GAAP adjusted EBITDA, “Earnings Before Interest, Taxes, Depreciation, and Amortization.”

These non-GAAP disclosures have limitations as an analytical tool, should not be viewed as a substitute for Gross Profit or Net Earnings (Loss) determined in accordance with U.S. GAAP, should not be considered in isolation or as a substitute for analysis of our results as reported under U.S. GAAP, nor are they necessarily comparable to non-GAAP performance measures that may be presented by other companies. STRATA considers these non-GAAP measures in addition to its results prepared under current accounting standards, but they are not a substitute for, nor superior to, U.S. GAAP measures. These non-GAAP measures are provided to enhance readers’ overall understanding of STRATA’s current financial performance and to provide further information for comparative purposes. This supplemental presentation should not be construed as an inference that the Company's future results will be unaffected by similar adjustments to Gross Profit or Net Earnings (Loss) determined in accordance with U.S. GAAP. Specifically, STRATA believes the non-GAAP measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of the Company’s core operating results and business outlook. In addition, STRATA believes non-GAAP measures enhance the comparability of results against prior periods.

Reconciliation to the most directly comparable U.S. GAAP measure of all non-GAAP measures included in this press release is as follows:

	Three Months EndedSeptember 30,								Nine Months EndedSeptember 30,
		2024				2023				2024				2023
Net loss	$	(2,122	)		$	(1,053	)		$	(5,589	)		$	(7,036	)
Adjustments:
Depreciation and amortization		1,239				1,449				3,738				4,274
Amortization of operating lease right-of-use assets		81				89				255				257
Loss on disposal of property and equipment		19				31				38				55
Interest expense, net		469				438				1,425				964
Non-GAAP EBITDA		(314	)			954				(133	)			(1,486	)
Employee retention credit		—				—				(864	)			—
Stock-based compensation expense		26				337				301				1,014
Inventory write-off		—				—				141				—
Loss on debt extinguishment		—				—				—				909
Non-GAAP adjusted EBITDA	$	(288	)		$	1,291			$	(555	)		$	437

XTRAC Gross Domestic Recurring Billings

XTRAC gross domestic recurring billings represent the amount invoiced to partner clinics when treatment codes are sold to the physician. It does not include normal GAAP adjustments, which are deferred revenue from prior quarters recorded as revenue in the current quarter, the deferral of revenue from the current quarter recorded as revenue in future quarters, adjustments for co-pay and other discounts. This excludes international recurring revenues.

The following is a reconciliation of non-GAAP XTRAC gross domestic billings to domestic recorded revenue for the third quarter and first nine months of 2024 and 2023 (in thousands), respectively:

	Three Months Ended September 30,								YTD
		2024				2023				2024				2023
Gross domestic recurring billings	$	4,813			$	4,883			$	14,126			$	14,675
Co-Pay adjustments		(84	)			(85	)			(247	)			(256	)
Other discounts		(19	)			(29	)			(76	)			(87	)
Deferred revenue from prior quarters		1,812				2,005				5,337				6,201
Deferral of revenue to future quarters		(1,867	)			(1,913	)			(5,580	)			(5,943	)
GAAP Recorded domestic revenue	$	4,655			$	4,861			$	13,560			$	14,589

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.

Investor Contact:CORE IR516-222-2560IR@strataskin.com

STRATA Skin Sciences, Inc. and SubsidiaryCondensed Consolidated Balance Sheets(in thousands, except share and per share data)
	September 30, 2024				December 31, 2023
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	7,062			$	6,784
Restricted cash		1,334				1,334
Accounts receivable, net of allowance for credit losses of $159 and $222 at September 30, 2024 and December 31, 2023, respectively		4,443				4,440
Inventories		2,744				2,673
Prepaid expenses and other current assets		297				312
Total current assets		15,880				15,543
Property and equipment, net		10,387				11,778
Operating lease right-of-use assets		1,348				626
Intangible assets, net		5,840				7,319
Goodwill		6,519				6,519
Other assets		231				231
Total assets	$	40,205			$	42,016
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	1,749			$	3,343
Accrued expenses and other current liabilities		8,524				6,306
Deferred revenues		2,421				2,120
Current portion of operating lease liabilities		322				352
Current portion of contingent consideration		1,030				53
Total current liabilities		14,046				12,174
Long-term debt, net		15,153				15,044
Deferred revenues and other liabilities		379				552
Deferred tax liability		186				186
Operating lease liabilities, net of current portion		1,002				237
Contingent consideration, net of current portion		96				1,135
Total liabilities		30,862				29,328
Commitments and contingencies (Note 14)
Stockholders’ equity:
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding		—				—
Common stock, $0.001 par value; 150,000,000 shares authorized; 4,171,161 and 3,506,025 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively		4				4
Additional paid-in capital		252,986				250,742
Accumulated deficit		(243,647	)			(238,058	)
Total stockholders’ equity		9,343				12,688
Total liabilities and stockholders’ equity	$	40,205			$	42,016

STRATA Skin Sciences, Inc. and SubsidiaryCondensed Consolidated Statements of Operations(in thousands, except share and per share data)(unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Revenues, net	$	8,797			$	8,852			$	23,986			$	24,669
Cost of revenues		3,490				3,898				10,662				11,009
Gross profit		5,307				4,954				13,324				13,660
Operating expenses:
Engineering and product development		243				248				683				937
Selling and marketing		3,048				3,038				9,080				10,196
General and administrative		3,669				2,283				8,589				7,690
Total operating expenses		6,960				5,569				18,352				18,823
Loss from operations		(1,653	)			(615	)			(5,028	)			(5,163	)
Other (expense) income:
Loss on debt extinguishment		—				—				—				(909	)
Interest expense		(537	)			(528	)			(1,592	)			(1,112	)
Interest income		68				90				167				148
Other income		—				—				864				—
Total other expense		(469	)			(438	)			(561	)			(1,873	)
Net loss	$	(2,122	)		$	(1,053	)		$	(5,589	)		$	(7,036	)
Net loss per share of common stock, basic and diluted	$	(0.53	)		$	(0.30	)		$	(1.52	)		$	(2.02	)
Weighted average shares of common stock outstanding, basic and diluted		4,038,988				3,491,113				3,684,976				3,488,465

STRATA Skin Sciences, Inc. and SubsidiaryCondensed Consolidated Statements of Cash Flows(in thousands)(unaudited)
	Nine Months EndedSeptember 30,
		2024				2023
Cash flows from operating activities:
Net loss	$	(5,589	)		$	(7,036	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		3,738				4,274
Amortization of operating lease right-of-use assets		255				257
Amortization of deferred financing costs and debt discount		109				112
Change in allowance for credit losses		(40	)			(205	)
Stock-based compensation expense		301				1,014
Loss on disposal of property and equipment		38				55
Inventory write-off		141				—
Loss on debt extinguishment		—				909
Changes in operating assets and liabilities:
Accounts receivable		37				(126	)
Inventories		14				(209	)
Prepaid expenses and other assets		15				388
Accounts payable		(1,638	)			(268	)
Accrued expenses and other liabilities		2,176				(611	)
Deferred revenues		170				(165	)
Operating lease liabilities		(242	)			(279	)
Net cash used in operating activities		(515	)			(1,890	)
Cash flows from investing activities:
Purchase of property and equipment		(1,132	)			(3,301	)
Net cash used in investing activities		(1,132	)			(3,301	)
Cash flows from financing activities:
Payment of contingent consideration		(18	)			(42	)
Proceeds from long-term debt		—				7,000
Issuance of stock		1,943				—
Payment of deferred financing costs		—				(97	)
Net cash provided by financing activities		1,925				6,861
Net increase in cash, cash equivalents and restricted cash		278				1,670
Cash, cash equivalents and restricted cash at beginning of period		8,118				6,795
Cash, cash equivalents and restricted cash at end of period	$	8,396			$	8,465
Cash and cash equivalents	$	7,062			$	7,131
Restricted cash		1,334				1,334
Total cash, cash equivalents and restricted cash	$	8,396			$	8,465
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	$	1,490			$	917
Supplemental schedule of non-cash operating, investing and financing activities:
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	$	977			$	—
Transfer of property and equipment to inventories	$	226			$	234
Accrued payment of contingent consideration	$	44			$	—
Modification of common stock warrants	$	—			$	384
Accrued exit fee recorded as debt discount	$	150			$	450
Change in intangible assets and fair value of contingent consideration	$	—			$	5,616